Metraipolis › archive › dc_950c111baf2d

Role of Intermediate dose escalation of radiotherapy in the survival of unresectable stage III non-small cell lung cancer patients in the era of immunotherapy — Europe PMC PMID:41685294

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41685294
DOI
10.3389/fonc.2025.1652522
License (as archived)
solo-consultazione
Archived
2026-11-06T11:28:22.150Z
SHA-256 of the archived text
9ab4ffdd7d8be215ec3b24368a026b69027518f17774dde23e33aab45f984ebc
Stable URL of this page
https://metraipolis.com/documento/dc_950c111baf2d

How to cite

Role of Intermediate dose escalation of radiotherapy in the survival of unresectable stage III non-small cell lung cancer patients in the era of immunotherapy — Europe PMC PMID:41685294 — Europe PMC (en), https://europepmc.org/article/MED/41685294 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_950c111baf2d (Metraipolis archive dc_950c111baf2d, sha256 9ab4ffdd7d8be215ec3b24368a026b69027518f17774dde23e33aab45f984ebc)
BibTeX
@misc{dc950c111baf2d,
  title = {Role of Intermediate dose escalation of radiotherapy in the survival of unresectable stage III non-small cell lung cancer patients in the era of immunotherapy — Europe PMC PMID:41685294},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41685294},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_950c111baf2d; sha256 9ab4ffdd7d8be215ec3b24368a026b69027518f17774dde23e33aab45f984ebc},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41685294. Agents can read the archived copy with the MCP tool read_document.